Bloom syndrome is an autosomal recessive human genetic disease that clinically presents low body weight at birth, stunted growth, cutaneous rash, and immunological deficiency (1, 2) . Individuals with Bloom syndrome are predisposed to infection and are cancer prone (3, 4) . Currently, individuals with this disease cannot be readily identified prior to the appearance of clinical symptoms. Bloom syndrome cells are characterized by their high rates of chromosomal aberration (5, 6) , spontaneous hypermutability (7) (8) (9) , hypersensitivity to environmental agents (10) (11) (12) , and a unique series of temporal alterations in the proliferativedependent regulation of DNA repair (13) (14) (15) . In particular, the cells fail to enhance DNA repair pathways prior to the initiation of DNA replication during the cell cycle. As a result, miscoding lesions remaining in the DNA are evidenced by hypermutability and chromosomal aberrations that contribute to the debilitation in this human genetic syndrome.
To begin to examine the regulation of the involved genes in Bloom syndrome at a molecular level, a series of monoclonal antibodies were prepared against the uracil DNA glycosylase of normal human placenta (16) . The uracil DNA glycosylase excises uracil from DNA during base-excision repair (17) (18) (19) . Uracil can arise from the utilization of dUTP instead of TTP during DNA synthesis (20) and by cytosine deamination (21) . Detailed analyses have shown that three of these antibodies recognize different determinants on the placental glycosylase molecule (22) . An early finding raised the possibility that the uracil DNA glycosylase in Bloom syndrome could be potentially characterized by a unique reaction to one monoclonal antibody (23) . Accordingly, we examined whether altered reactivity of the glycosylase with this monoclonal antibody, 40.10 .09, has the potential to be used as a negative marker for Bloom syndrome. We report here the immunological properties of the uracil DNA glycosylase from 24 diverse human sources. Cell strains were grown in humidified 5% C02/95% air in Dulbecco's modified Eagle's medium (GIBCO) supplemented with 2 mM glutamine, 10%o fetal calf serum, and 100 units of penicillin and 100 mg of streptomycin per ml (13, 14) . Cells were harvested at confluence and sonicated at 60 W for 20 sec. Cell debris was pelleted by centrifugation. Uracil DNA glycosylase from each cell strain was then purified by gradient elution through DEAE-cellulose and then phosphocellulose column chromatography (22) .
Monoclonal Antibodies. Monoclonal antibodies against normal human uracil DNA glycosylase were prepared as described (16 The publication costs of this article were defrayed in part by page charge payment. This article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. §1734 solely to indicate this fact.
plates. Each plate was incubated at 370C for 2 hr and then at 40C for 48-72 hr. The wells were washed twice with Dulbecco's phosphate-buffered saline (PBS) followed by a 30-min incubation with 1% (wt/vol) bovine serum albumin in PBS at 370C (200 ul per well). Each well was rinsed twice with PBS. For storage, 100 gl of PBS was added to each well and removed just prior to analysis. Monoclonal antibodies (1 ng/pul) were added in aliquots of 50 jul and incubated for 2 hr at 370C. Each well was rinsed with washing buffer (New England Nuclear; 10 mM Tris*HC1, pH 8.0/0.05% Tween 20) . Sheep alkaline phosphatase-conjugated F(ab')2 fragment anti-mouse IgG antiserum (New England Nuclear) as second antibody was then applied (50 1.l of a 1:250 dilution) for 2 hr at 370C; the wells were washed once with washing buffer followed by two washes with deionized-distilled water. Immunoreactivity with the second antiserum was detected by incubation with 0.05 M p-nitrophenyl phosphate as substrate in the dark for 16 hr at 250C. The reaction was ended by addition of 50 1.l of 1 M NaOH. Colorimetric determinations were performed at 405 nm with a Uniskan plate reader.
Uracil DNA Glycosylase Assay. Uracil-containing polynucleotide substrate was prepared by using Escherichia coli DNA polymerase I and [3H]dUTP as precursor (25) . Uracil DNA glycosylase was determined in a reaction mixture (final volume, 100 1,u) that contained 100 mM Tris*HCl (ph 8.0)/10 mM K2EDTA/5 mM dithiothreitol/1 ,ul of poly(dA).poly ([3H]dU) (specific activity, 5,000-15,000 dpm/pmol), and 1-2 ,ug of purified enzyme or cell extract. The mixture was incubated for 30 min at 37°C. The reaction was terminated by the addition of 300 ,ul of 95% ethanol (-20°C), 60 ,u1 of 2 M NaCl, and 100 ,u1 of 1 mg/ml heat-denatured calf thymus DNA. The ethanol precipitate was collected by centrifugation at 2300 x g for 10 min at 4°C. Uracil DNA glycosylase activity was measured by the release of [3H]uracil into the ethanol supernatant.
RESULTS
Immunoreactivity of Bloom Syndrome Uracil DNA Glycosylase. The ELISA reactivity of the glycosylase of each Bloom syndrome cell strain was examined with all of the monoclonal antibodies raised against the normal enzyme. Each Bloom syndrome enzyme reacted with antibodies 37.04.12 and 42.08.07 ( Fig. 1 A and B ) in a concentration-dependent manner, identical to that of the glycosylase purified from normal human fibroblasts ( Fig. 1 A and B) and the homogeneous human placental enzyme (22) . In contrast, the glycosylase from all five Bloom syndrome cell strains failed to react with the marker monoclonal antibody, 40.10.09 (Fig.  1C) . Further, this lack of recognition of the Bloom syndrome glycosylase was observed in ELISA, even when 10 ,ug (100-fold excess) of the Bloom syndrome glycosylase preparations was used. However, ELISA immunoreactivities to this same marker antibody (40.10.09) were observed with the normal human fibroblast enzyme (Fig. 1C) and with the placental enzyme (22) .
The reactivity of each Bloom syndrome glycosylase was also studied in terms of enzyme inhibition by glycerol gradient sedimentation analysis (16) . First, normal human fibroblast glycosylase was preincubated with each type of anti-glycosylase antibody or with the control antibody, 1.05 (Fig. 2, A-C) . In each instance, uracil DNA glycosylase activity sedimented near the top of the gradient. Preincubation of the normal enzyme with each glycosylase monoclonal antibody resulted in a loss of activity. Noteworthy is the fact that the most significant inhibitions occurred when the normal enzyme was preincubated with either antibody 37 .04.12 ( Fig. 2A) or the marker antibody, 40 .10.09 (Fig.  2C) . As each antibody inhibited catalysis, the glycosylase-antibody complex that sediments at a higher density could not be detected (16) . In contrast, this second peak of activity could be observed by using an anti-DNA polymerase a monoclonal antibody that recognizes the glycosylase when it is bound to the polymerase (16, 26) .
The ability of each monoclonal antibody to inhibit the Bloom syndrome glycosylase (GM 2548) was then ascertained. Significant enzyme inhibitions occurred when the Bloom syndrome enzyme was preincubated with either monoclonal antibodies 37.04.12 or 42.08.07 (Fig. 2 D and E) . The extent of inhibition was virtually identical to that observed in their reactions with the normal human fibroblast enzyme. In contrast, marker monoclonal antibody 40.10 .09 failed to inhibit the Bloom syndrome glycosylase (Fig. 2F) 40.10 .09 (Fig. 3, lanes 1-5) . Further, only one immunoreactive species of Mr 37,000 was detected, corresponding to the molecular size of the normal human fibroblast glycosylase (Fig. 3,  lane 7) and the homogeneous human placental enzyme (Fig.  3, lane 6 ). These findings suggest that each Bloom syndrome glycosylase shares a common aberration in its native struc- First, we evaluated the ELISA reactivities of the glycosylase from the following five different normal human cell types: two different human skin fibroblast cell strains, one embryonic lung fibroblast cell strain, human lymphocytes, and several different placental preparations. The extent of recognition was at all times comparable to that observed for the normal human skin fibroblast enzyme. Similarly, a simian virus 40-transformed human cell line exhibited normal ELISA reactivity, even though viral transformation can dramatically affect the capacity for human DNA repair (27, 28) .
We also evaluated the ELISA immunoreactivities of the glycosylase of fibroblasts from a variety of human genetic disorders. Like individuals with Bloom syndrome, those with ataxia telangiectasia and xeroderma pigmentosum are cancer prone (19) . Further, xeroderma pigmentosum cells of complementation groups A, C, and D fail to enhance nucleotide-excision repair during the cell cycle (29) . However, each complementation group regulates in a normal fashion both base-excision repair and the uracil DNA glycosylase. The uracil DNA glycosylase protein from two different ataxia telangiectasia cell strains and three different xeroderma pigmentosum cell strains displayed normal ELISA immunoreactivity with all three monoclonal antibodies. The xeroderma pigmentosum cells included different complementation groups (C and D) as well as the xeroderma pigmentosum variant. Progeria is characterized by premature aging (30) and possibly by altered capacity of DNA repair (31, 32) . Normal immunoreactivity was observed when using the glycosylase from two different progeroid cell strains.
ELISA immunoreactivities of the glycosylases from three other human genetic syndromes were determined. Bloom syndrome and Tay-Sachs disease arise with frequencies of approximately 1/120 and 1/30 in the Ashkenazic Jewish population, respectively (33, 34) . The Tay-Sachs uracil DNA glycosylase displayed normal immunoreactivity (Table  1) . ELISA was also performed on two genetic syndromes characterized by other metabolic disorders. Normal reactivity was observed with each of the three anti-human glycosylase monoclonal antibodies.
DISCUSSION
This report provides evidence that raises the possibility of a method by which to identify Bloom syndrome prior to the onset of clinical symptoms. The altered immunoreactivity of the Bloom syndrome glycosylase with antibody 40.10.09 demonstrates that this antibody may serve as a negative marker of this human genetic disease. In common with Tay-Sachs disease, Bloom syndrome heterozygotes do not appear to manifest clinical symptoms. However, in TaySachs disease, heterozygotes may be identified by the expression of the mutant allele. Bloom syndrome cell strains derived from such individuals are currently unavailable. As the uracil DNA glycosylase is easily analyzed in blood samples (35) , family studies of Bloom syndrome individuals can be performed to examine the expression of the altered glycosylase in heterozygotes.
Although antibody-antigen interactions depend on the amino acid sequence that specifies the primary determinant, immunoreactivity may also depend on the secondary or tertiary structure of the protein (36) . Further, independent of the primary antigenic determinant, immunoreactivity may be affected by alterations of epitope structure, including protein folding (37 This laboratory has previously reported that Bloom syndrome may be characterized by several alterations in the proliferation-dependent regulation of DNA repair, including the temporal displacement of nucleotide-excision repair after UV irradiation, base-excision repair after exposure to methylmethane sulfonate, and abnormal regulation of the uracil DNA glycosylase and the hypoxanthine DNA glycosylase enzymes (13, 14) . In each instance, DNA repair capacity was not enhanced prior to DNA replication but was increased coordinately with DNA synthesis. Further, no induction of the 06-methylguanine methyltransferase was observed (15) . These regulatory defects were postulated to result in the aberrant replication of the cell's genetic information before there is the opportunity to correct the DNA or to remove accumulated DNA lesions. This altered regulation of the uracil DNA glycosylase was subsequently reported in a cell strain from a Japanese Bloom syndrome patient (38) .
In addition, recent analysis demonstrated a 50% decrease in Fig. 1 ). Absorbances at each protein concentration were performed in duplicate. Cells were cultured as described herein; cell extracts were prepared as previously described (13, 14) . SV40, simian virus 40. Proc. Natl. Acad. Sci. USA 85 (1988) DNA ligase I in Epstein-Barr virus-transformed Bloom syndrome cell lines (39, 40) . Each of these alterations in DNA repair capacity appears to be separate and independent. However, genetic studies demonstrate that Bloom syndrome is an autosomal recessive human genetic disease, presumably localizing the molecular defect within a single gene. Thus, it would appear that each defect in DNA repair capacity, including the results presented in this report, may represent alterations characteristic of the Bloom syndrome phenotype but secondary to the primary genetic defect. At present, that single defect remains unknown. Alternatively, these series of repair-enzyme regulatory alterations may indicate a corecessive pattern of inheritance for Bloom syndrome (41) . In either instance, molecular analysis of DNA-repair structural genes may identify one or more genomic aberrations that can result in separate changes that include the alteration of the amino acid sequence of the uracil DNA glycosylase protein.
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